Until now, 14 CHKA inhibitors have been proposed at Research Collaboratory for Structural Bioinformatics (RCSB), among which TCD-717 has completed a phase I clinical trial and displayed long-term toxic antitumor efficacy in colon adenocarcinomas, non-lung squamous cell carcinomas, and breast adenocarcinomas [27,28,29,30]. This evidence concerns the gene CHKA and squamous cell lung carcinoma.